AQEMIA’s Post

Exciting article!: "Immersed at… Iktos, the startup that relies on AI to accelerate the discovery of new drugs." Maddyness recently explored the heart of innovation at the Iktos headquarters in Paris, France. Their latest article delves into our mission to propel the pharmaceutical industry forward by seamlessly merging #artificialintelligence and #robotics. Together, we’re pushing the boundaries and expediting #drugdiscovery. Read the full feature here: https://lnkd.in/eEKUkveN

🔬💡 Bridging Innovation: Transforming Pharmaceutical Research in Wallonia and Brazil 🌍🧪     Let's embark on a journey of innovation and collaboration as we delve into the remarkable partnership between Wallonia and Brazil in the realm of pharmaceutical research! With Princess Astrid's upcoming economic mission to Brazil in November 2024 on the horizon, let's shine a spotlight on the transformative initiatives driving healthcare advancements in the world. 🇧🇪 DID YOU KNOW THIS ABOUT WALLONIA: Quantum BioVenture Studio is redefining drug discovery in Wallonia by combining AI and entrepreneurship under the visionary leadership of Florence Bosco. With a focus on accelerating treatment discovery, the studio leverages AI to create biotech startups and collaborate with key partners, reshaping the future of pharmaceutical research in the region and beyond.   🇧🇷 DID YOU KNOW THIS ABOUT BRAZIL: In Brazil, organizations like Dasa, Instituto Butantan, Biominas Brasil, and Fleury Medicina e Saúde are pioneering advancements in life sciences and pharmaceutical research. From improving diagnostics to developing vaccines, these institutions are potential candidates for integrating AI and entrepreneurship into their processes, mirroring the innovative spirit of Quantum BioVenture Studio in Wallonia.   As we explore the transformative potential of AI and entrepreneurship in pharmaceutical research, it's worth highlighting a recent milestone: Quantoom Biosciences, an arm of UNIVERCELLS and a Walloon company specializing in messenger RNA technology, has sealed a groundbreaking partnership with Bio-Manguinhos / Fiocruz, an arm of Fiocruz. This collaboration underscores the global reach and impact of innovative partnerships in advancing healthcare solutions. 🚀💊🌍 Wallonia Export & Investment Agency | Belgian Foreign Trade Agency (BFTA) | Wallonie Bruxelles International | Skywin | BioWin - The Health Cluster of Wallonia | Wagralim, the Agri-Food Innovation Cluster of Wallonia | Logistics in Wallonia | GreenWin | Pôle MecaTech | Centre Logistique de Wallonie https://lnkd.in/ddrsJ6aG

COVID is not over for the immunosuppressed, long-COVID patients (with increasing evidence of a virus reservoir), and we need to get ready for a next SARS-like virus, given we had 2 outbreaks in 20 years. Patient work has been ongoing VIB-UGent Center for Medical Biotechnology and ExeVir to engineer a cocktail consisting of 2 antibodies with unique mechanisms of action that have resisted all SARS-CoV-2 evolution under human immune pressure sofar. The teams are keen to let you know much more about the journey there, in due time. https://lnkd.in/esgSyEVM

🎤 International Conference At #Patrys, we are always excited to learn of the promising potential of our deoxymab technology in new areas of clinical need. This week, we are pleased to announce that new data from preclinical studies using PAT-DX1 in animal models of anti neutrophil cytoplasmic antibody (ANCA) vasculitis will be presented at the 21st International Vasculitis Workshop in Barcelona next month. Dr Kim O’Sullivan from Monash University will present on recent preclinical studies that demonstrate the potential to improve treatments for autoimmune diseases like ANCA vasculitis, an inflammatory condition caused by the buildup of of activated neutrophils and neutrophil extracellular traps (NETs) in small blood vessels. Current treatments increase the risk of infections, highlighting the need for safer therapies. Patrys Chief Executive Officer and Managing Director, Dr James Campbell, said: “As GMP manufacturing for PAT-DX1 remains on track to commence in the current quarter, it is exciting to identify additional therapeutic opportunities for our deoxymab platform with promising future partnering and licensing opportunities for Patrys.” Read today’s ASX release 👉 https://lnkd.in/gX2efc9W $PAB #ASX #biotech #innovation #antibodies #vasculitis #conference 

We'll share more real-world cases during 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐯𝐞 𝐁𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬 𝐚𝐧𝐝 𝐂𝐌𝐂 𝐂𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞𝐬 and illustrate how 2 Bridge 𝐓𝐢𝐠𝐞𝐫 T𝐞𝐚𝐦s support startups and venture capitals to build successful biotech companies. More info about the event 👉 https://lnkd.in/eZpWEHue

Another interesting model involving in-house discovery and company creation, focusing on a wide range of medical needs and utilizing advanced platform technologies, while aiming to be self-sustaining by reinvesting profits from its discoveries. #biotech #ai #companycreation #boston #drugdiscovery #biomanufacturing #lifesciences #venturecapital #ml #robotics

The stage between discovery and human testing is called the ‘valley of death’ in drug development. Though it exists in the early development of all drugs (due to the high risk of scientific failure), it is particularly problematic with antibiotics. Here’s how Phare Bio is addressing the issue using a philanthropic model and AI for good: https://virg.in/4b0QPYj Phare Bio Virgin Unite The Audacious Project

Meeting a unique team was such an honour! ARTHEx Biotech is an EIC Accelerator beneficiary, based in Spain. I met this dynamic and hard working team at their premises in Valencia, where the heart of the company is beating, modulating microRNAs and developing innovative medicines, tailored to patients’ specific needs. EIC Accelerator blended finance is awarded for the development of a brand new treatment to Myotic Dystrophy Type 1 (DM1), an orphan disease affecting more than 900,000 people worldwide (estimated prevalence 1/8,000). This condition has currently no cure, and no approved treatment. A first-in-class disease modifying therapy, ATX-01, developed by ARTHEx, addresses the cause of DM1 with a dual and unique mechanism of action, which targets micro-RNA-23b a key factor in the disease pathogenesis. ARTHEx biotech is a spin-off biotech company from the University of Valencia. They have grown from 1 person in 2019 when the company was founded to a team of 20 right now. The EIC Accelerator grant is used to support Phase I/IIa clinical trial of ATX-01 for DM1. beatriz llamusi PhD, CSO & Co-Founder of ARTHEx biotech mentioned: “This grant empowers us to bridge the gap between foundational scientific research and clinical application, driving the development of ATX-01 for DM1. With its dual mechanism, we're confident in our potential to set a new standard in treatment within the DM1 space.”   It is simply amazing to see European players raising up to their potential to bring best-in-class treatments in the global fight against rare diseases. To learn more about their approach and pipeline visit ARTHEx Biotech https://lnkd.in/ddBQyg-E #EUeic, #eicAccelerator #MyotonicDystrophy #biotech #financing #microRNA  

"AI will be assisting pathologists, not replacing them". Hearing about the struggles of the local disease diagnostics industry, particularly the very manual nature of pathology, from Daniel Lim of VIDANEX, it seemed only natural to progress towards digitisation; but I was surprised by how far behind Malaysia and the region is in this regard. The incorporation of AI to optimise bio-based workflows is a no-brainer. Faster, more accurate disease diagnoses = more lives saved. While further research needs to be done to validate the tech, if anyone would get there soon, it would be this Bio-Based Accelerator company. #biotech #AImedicaldevices

📅 Tuesday 4 June at 2 pm Panel discussion: « from lab to market : how can the technology transfer office facilitate in advancing healthcare innovation ? » We are thrilled to welcome you on stand#3823 for the panel at Pavilion France, that we have co-organized with Business France, moderated by Lise ALTER, Managing Director of the French Health Innovation Agency with testimonials from industrial partners on the importance of the synergies between academic research and the private sector, the need of sharing knowledge and highlight how TTOs can facilitate the interaction between both worlds: 🎤Speakers: · Pascale Auge, Chairman of the Executive Management Board Inserm Transfert will present the expertise and the know-how of Inserm Transfert in technology transfer. · Dominic King-Smith, Ph.D., President and CEO of EnZen Therapeutics, Inc., · Jesús Baena, Global BD&L Transactions Director at Novartis Business France Healthcare - North America - Business France – Santé - Business France (Invest in France) #FrenchHealthcare #ChooseFrance #BIO2024